RxDoctor Payments Data

Giovanni Campagna, MD

Glaucoma Specialist · Saint Louis, MONPI 1760942684

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $34,923 of the $56,201 with a category attached, or 62.1%. 14 manufacturers reported payments, led by Alcon at 44.9% of the total. 2025 is the largest year on record at $49,545, more than ten times the $365 reported in 2021.

$56,201in general payments, 2019–2025

Across 134 payments — averaging $419.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$25K
  • Glaukos Corporation$12K
  • Bausch & Lomb Americas Inc.$9K
  • Alcon Research LLC$5K
  • NEW World Medical,inc.$2K
  • Sight Sciences, Inc.$1K
  • plus $1K from 8 others

What the payments were for

  • Consulting fees$34,92362%
  • Speaking & faculty fees$8,65015%
  • Travel & lodging$5,2249%
  • Food & beverage$7,07613%
  • Education$3281%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$70,213
Medicare patients
131
Services billed
446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost31$16,751
LumiganBimatoprost28$12,559
Brimonidine Tartrate169$7,197
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$6,601
CombiganBrimonidine Tartrate/Timolol20$4,498
SimbrinzaBrinzolamide/Brimonidine Tart14$3,862
RhopressaNetarsudil Mesylate12$3,741
Prednisolone Acetate107$3,662
Latanoprost401$3,447
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat189$2,369
Brinzolamide15$1,689
Dorzolamide Hcl83$1,237
Travoprost12$1,042
Ketorolac Tromethamine65$937
MoxifloxacinMoxifloxacin Hcl39$753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$404$17,05748 claims
AlconSimbrinza$25,259$3,86214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Missourion file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →